

Publications

- More than 50 scientific publications in scientific journals

a. Articles in Peer-Reviewed Journals

1. Bafaloukos D, Samonis G, Klinaki A, **Daliani D**, Karvounis N, Bakoyannis C, Karabelis A, Mylonakis N, Kosmidis P: First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer. *Eur J Cancer* 29A(6): 851-853, 1993.
2. Tsavaris N, Tentas K, Bacoyiannis C, Katsikas M, Sakelaropoulos N, Kosmas C, **Daliani D** and Kosmidis P: 5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: A pilot study. *Anti-Cancer Drugs* 6(4): 599-603, 1995.
3. Tsavaris N, Mylonakis M, Bacoyiannis C, Karvounis N, Charalambidis G, Pagou M, Lioni A, **Daliani D** and Kosmidis P: Efficacy of ondacetron treatment with different timing schedules: a randomized double-blind study. *Oncology* 52(4): 315-318, 1995.
4. Tsavaris N, Mylonakis N, Bacoyiannis C, Karvounis N, Kordossis T, **Daliani D**, Karabelis A, Kosmidis P.: Use of naproxen in ameliorating induced paraneoplastic fever. *Clin Drug Invest* 10 (1): 8-11, 1995.
5. **Daliani D**, Weber D, Alexanian R: Light and Heavy Chain Deposition Disease (LHCDD) progressing to multiple myeloma. *Am J Hematol* 50: 296-298, 1995.
6. **Daliani D**, Eisenberg P, Weems J, Lord R, Fueger R, Logothetis C: The results of a phase II randomized trial comparing 5-FU and 5-FU+a-IFN: Observations on the design of clinical trials for Androgen-Independent Prostate Cancer. *J Urol* 153: 1587-1591, 1995.
7. Sarris AH, **Daliani D**, Ulmer R, Crow M, Broxmeyer HE, Pugh W, Reiss M, Cabanillas F, Deisseroth AB and Duvic M: Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. *Leukemia-Lymphoma* 24: 103-110, 1996.
8. Sarris AH, **Daliani D**, Ulmer R, Crow M, Broxmeyer HE, Reiss M, Karassavas N, Zelenetz AD, Pugh W, Cabanillas F, Deisseroth AB and Duvic M: Interferon-Inducible Protein-10 as a possible factor in the epidermotropism of cutaneous T-cell lymphomas. *Clinical Cancer Research* 3: 169-177, 1997.
9. Dimopoulos MA, **Daliani D**, Pugh W, Cabanillas F and Sarris AH: Primary ovarian lymphoma: outcome after treatment with combination chemotherapy. *Gyn Oncol*, 64: 446-450, 1997.
10. **Daliani D**, Ulmer RA, Jackow C, Pugh W, Gansbacher B, Cabanillas F, Duvic M, and Sarris AH: Tumor necrosis factor- α , interferon- γ and interferon-inducible protein-10 but not HTLV-I tax are likely factors in the epidermotropism of cutaneous T-cell lymphoma. *Leukemia-Lymphoma*, 29: 315-328, 1998.
11. Bublely G, Carducci M, Dahut W, Dawson N, **Daliani D**, Eisenberger M, Figg W, Freidlin B, Halabi S, Judes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak D, Reed E, roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small E, Smith M, Trump D, Bollmer R, Wilding G: Eligibility and response guidelines

- for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA working group. Journal of Clinical Oncology, 17: 3461-3467, 1999.
12. Papandreou CN, Pagliaro L, Millikan R, **Daliani D**, Hermann J, Hong Y, Smith M, Adams J, Elliot P, Lightcap E, McCormack T, Pien C, Newman R, Logothetis CJ: Phase I Study of PS-341, A Novel Proteasome Inhibitor, in patients with Advanced Malignancies. Clin Cancer Res 5:3730S, Suppl S, 1999.
 13. Amato RJ, Millikan R, **Daliani D**, Wood L, Logothetis C, Pollack A: Cyclophosphamide and Carboplatin and Selective Consolidation in Advanced Seminoma. Clinical Cancer Research 6(1): 72-7, 2000.
 14. The Prostate Cancer Trialists' Collaborative Group (PCTCG): Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet, 355: 1491-98, 2000.
 15. Pagliaro L, **Daliani D**, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R: A phase II trial of Bryostatins-1 for patients with metastatic renal cell carcinoma. Cancer 89(3): 615-618, 2000.
 16. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, **Daliani D**, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted Therapy for Advanced Androgen-Independent Carcinoma of the Prostate: A Randomized Phase II Trial. Lancet; 357: 336-341, 2001.
 17. Logothetis CJ, Wu KK, Finn LD, **Daliani D**, Figg W, Ghaddar H, Gutterman JU: Phase I Trial of the Angiogenesis Inhibitor TNP-470 for Progressive Androgen-Independent Prostate Cancer Clinical Cancer Research 7: 1198-1203, 2001.
 18. Mian BM, Bhadkamkar N, Slaton JW, Pisters PWT, **Daliani D**, Swanson D, Pisters LL: Prognostic factors and survival in patients with sarcomatoid renal cell carcinoma. J Urol, 167:65-70, 2002.
 19. **Daliani D**, Papandreou C, Thall PF, Wang X, Perez C, Pagliaro L, Oliva R, Amato R: A Pilot Study of Thalidomide in Patients with Progressive Metastatic Renal Cell Carcinoma. Cancer 95:758-65, 2002.
 20. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, **Daliani D**, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ: Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(1): 1555-60, May 20, 2002.
 21. Pagliaro LC, Millikan RE, Tu SM, Williams D, **Daliani D**, Papandreou CN, Logothetis CJ: Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20(13): 2965-70, July 1, 2002.
 22. Papandreou CN, **Daliani D**, Thall PF, Tu SM, Wang X, Reyes A, Troncoso P, Logothetis CJ: "Results of a Phase II Study with Doxorubicin, Etoposide and Cisplatin in Patients with Fully Characterized Small Cell Carcinoma of the Prostate". J Clin Oncol, 20(14): 3072-3080, July 15, 2002.
 23. Nelson JB, Nabulsi AA, Vogelzang NJ, Breul J, Zonnenberg BA, **Daliani DD**, Schulman CC, Schmitt JL, Carducci MA: Suppression of Prostate Cancer-Induced Bone Remodeling by the Endothelin Receptor A Antagonist Atrasentan. J Urol, 169: 1143-1149, 2003.
 24. Carducci MA, Padley RJ, Bruel J, Vogelzang NJ, Zonnenberg BA, **Daliani D**, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: The Effect of Endothelin_A Receptor Blockade with Atrasentan on

- Tumor Progression in Men with Hormone-Refractory Prostate Cancer: A Randomized, Placebo-Controlled Trial. *J Clin Oncol*, 21(4): 679-689, 2003.
25. **Daliani D**, Assikis V, Tu S-M, Papandreou C, Pagliaro L, Holtkamp T, Wang X, Thall PF, Logothetis C: Phase II Trial of Cyclophosphamide, Vincristine and Dexamethasone in the Treatment of Androgen-Independent Prostate Cancer. *Cancer*, 97; 561-567, 2003.
 26. Tu SM, Millikan RE, Williams D, Pagliaro L, **Daliani D**, Papandreou CN, Kim J, Logothetis CJ: Treatment of Refractory Urothelial Carcinoma with Alternating Paclitaxel, Methotrexate, Cisplatin (TMP) and 5-Fluorouracil, α -Interferon, Cisplatin (FAP) *Urologic Oncology*, 21(5): 342-348, 2003.
 27. Siefker-Radtke AO, Gee J, Shen Y, Wen A, **Daliani D**, Millikan RE, Pisters LL: Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. *J Urol*, 169: 1295-1298, 2003.
 28. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, **Daliani D**, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM: prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduce expression of osteoprotegerin in osteoblasts. *Clinical Cancer Research*, 9(7): 2587-2597, 2003.
 29. Papandreou CN, **Daliani DD**, Yang H, Newman RA, Nix D, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliot P, Esseltine D, Petrusich A, Dieringer P, Perez CA, Logothetis CJ: Phase I Trial Of The Proteasome Inhibitor Bortezomib In Patients With Advanced Solid Tumors With Observations In Androgen-Independent Prostate Cancer. *J Clin Oncol*, 22:2108-2121, 2004.
 30. Mathew P, Logothetis CJ, Dieringer PV, Chen I, Pagliaro LC, Bekele BN, Zhou X, **Daliani DD**: Thalidomide/Estramustine/Paclitaxel in metastatic androgen-independent prostate cancer. *Clin Genitourinary Cancer* 5(2):144-149, 2006.
 31. Pagliaro LC, Perez CA, Tu S-M, **Daliani DD**: Phase II Study of Capecitabine Single-Agent Therapy in Patients with Metastatic Renal Cell Carcinoma *Urol Oncol*. 24(6):487-91, Nov-Dec; 2006.
 32. Faria SC., Ng CS, Hess KR. Phongkitkarun S, Szejnfeld J, **Daliani D**, Charnsangavej C : CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. *Am. J Roentgenology*. 189(2):378-85, 2007 Aug.
 33. [Mao S](#), **Daliani DD**, [Wang X](#), [Thall PF](#), [Do KA](#), [Perez CA](#), [Brown MA](#), [Bouchillon K](#), [Carter CM](#), [Logothetis CJ](#), [Kim J](#). Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. *Prostate*. 2007 Nov 1;67(15):1677-85.
 34. Daponte A, Kostopoulou E, Papandreou CN, **Daliani DD**, Minas M, Koukoulis G, Messinis IE: Prognostic significance of fascin expression in advanced poorly differentiated serous ovarian cancer. *Anticancer Res* 2008; 28(3B):1905-1910.
 35. **Daliani DD**, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. *BJU Int*. 2009 104(4): 456-460.

36. Vlachostergios PJ, Patrikidou A, **Daliani DD**, Papandreou CN: The Ubiquitin-Proteasome System in cancer, a major player in DNA Repair. Part 1: Post-translational regulation. J Cell Mol Med. 2009; 13(9B): 3006-18.
37. Vlachostergios PJ, Patrikidou A, **Daliani DD**, Papandreou CN: The Ubiquitin-Proteasome System in cancer, a major player in DNA Repair. Part 2: Post-transcriptional regulation. J Cell Mol Med. 2009; 13(9B): 3019-31.
38. Vlachostergios PJ, **Daliani DD**, Dimopoulos V, Patrikidou A, Voutsadakis JA, Papandreou CN: Non-bacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer. Oncologie 2010; 33(8-9):456-9.
39. Pagliaro LC, Willams DL, **Daliani D**, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010 Aug 20; 28(24): 3851-7.
40. [Patrikidou A](#), [Vlachostergios PJ](#), [Voutsadakis IA](#), [Hatzidaki E](#), [Valeri RM](#), [Destouni C](#), [Apostolou E](#), **Daliani D**, **Papandreou CN**.: Inverse baseline expression pattern of the NEP/neuropeptides and NFkappaB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int. 2011, Cancer cell international 2011;11(1):13.
41. Panagiotis J Vlachostergios; **Danai D Daliani**; Ioannis Gioulbasanis; Grigorios Kakkas; Kassiani Kapatou; Foteini Karasavvidou; George Moutzouris; Christos N Papandreou: Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer. Journal of Negative Results in Biomedicine 2012;11(1):2.
42. Ioannis A Voutsadakis; Panagiotis J Vlachostergios; **Danai D Daliani**; Grigorios Kakkas; Foteini Karasavvidou; Michael D Melekos; Georgios Moutzouris; Christos N Papandreou: CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy. Urologia Internationalis 2012;88(2):158-64.
43. Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Elias Zintzaras; Anna Patrikidou; **Danai D Daliani**; Grigorios Kakkas; Foteini Karasavvidou; Michael D Melekos; Georgios Moutzouris; Christos N Papandreou: Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomy. Prostate cancer 2012;2012():452795.
44. E Kouvaras; Christos N Papandreou; A Athanasiadis; **Danai D Daliani**; G K Koukoulis: Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2/CEP17 ratios, in "thin" and "thick" tissue sections. Breast (Edinburgh, Scotland) 2012;21(1):34-9.
45. Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Elias Zintzaras; Anna Patrikidou; **Danai D Daliani**; Grigorios Kakkas; Foteini Karasavvidou; Michael D Melekos; Georgios Moutzouris; Christos N Papandreou: p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-

naïve prostate cancer. Pathology oncology research : POR 2012;18(2):245-52.

46. Konstantinos Tsapakidis; Panagiotis J Vlachostergios; Ioannis A Voutsadakis; Anna Patrikidou; Christina D Befani; **Danai D Daliani**; Eleana Hatzidaki; Panagiotis Liakos; George Moutzouris; Christos N Papandreou Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. International journal of urology : official journal of the Japanese Urological Association 2012;19(6):565-74.

b. Invited Articles

1. **Daliani D**, Papandreou C: Markers of androgen-independent progression of prostatic carcinoma. Seminars in Oncology, 26(4): 399-406, 1999.
2. **Daliani D**, Development of angiogenesis inhibition as therapy for prostate cancer. Oncology 14 (Suppl 13) 21-23, 2000.

c. Letters to the Editor

1. Weber D, **Daliani D**, Alexanian R: Costly errors. (Letter to the editor). New Engl J Med, 333; 16:1080, 1995.
2. Sarris AH, **Daliani D**, Duvic M: Response: Cytokines and IP-10 in cutaneous T-cell lymphoma. Blood 88:758, 1996.

d. Books and Chapters

1. **Daliani D**, Patel S: Bone and Soft tissue Sarcomas. In: Pazdur R, ed.: Medical Oncology: A Comprehensive Review, pp: 511-529, 2nd ed. PRR, Inc, Huntington, NY. 1996.